Samaneh Kouzegaran1, Soheila Siroosbakht2, Bahram Fariborz Farsad3, Bijan Rezakhaniha4, Banafshe Dormanesh5, Vahid Behnod6, Amir Saber Tanha7. 1. Department of Pediatrics, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran. 2. Department of Pediatrics, AJA University of Medical Sciences, Tehran, Iran. 3. Rajaie Cardiovascular Medical and Research Center, Department of Pharmacotherapy, IIran University of Medical Sciences, Tehran, Iran. 4. Department of Urology, AJA University of Medical Sciences, Tehran, Iran. 5. Department of Pediatric Nephrology, AJA University of Medical Sciences, Tehran, Iran. 6. Department of Molecular Biology, Baqiyatallah University of Medical Sciences, Tehran, Iran. 7. Department of Anesthesia, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Abstract
BACKGROUND: In this study, we investigated the role and expression of interleukin (IL)-17A and IL-22 in chronic lymphocytic leukemia. METHODS: We evaluated the expression of markers above on CLL by ELISA, qRT-PCR, flow cytometric analysis and nonparametric Kruskal-Wallis test. RESULTS: Quantitative RT-PCR revealed that the mRNA levels of IL-17A and IL-22 in PBMCs of CLL patients were upregulated compared with those from healthy subjects (mean ± SD: 1.96 ± 0.232 vs.0.72 ± 0.15, P < 0.001 and mean ± SD: 2.45 ± 0.534 vs.0.81 ± 0.26, P < 0.001, respectivily). In addition, findings showed that the IL-17A and IL-22 plasma level was significantly elevated than that from healthy control group (P < 0.001). The median IL-17A and IL-22 in CLL patients and healthy control group were 48.28 ± 17.2 pg mL-1 ; 20.01 ± 11.16 pg mL-1 and 58.68 ± 23.4 pg mL-1 ;16.47 ± 10.31 P < 0.001, respectively. The levels of IL-17A and IL-22 was not significantly associated with the different stages of disease (Rai stages; Kruskal-Wallis test P > 0.05).No significant relationship was found between expression of CD38 and higher median serum levels of IL-17A in patients, but patients with negative expression of ZAP-70 showed a significant association with higher median serum levels of IL-17A compared with healthy subjects. (57.84 pg mL-1 vs. 31.67 pg mL-1 ; P = 0.016). CONCLUSION: IL-22 is elevated and associated with CD38 and Zap-70 expression in patients with CLL. No significant correlation was found between expression of CD38 and increased levels of IL-17A, negative expression of ZAP-70 showed a significant association with increased levels of IL-17A.
BACKGROUND: In this study, we investigated the role and expression of interleukin (IL)-17A and IL-22 in chronic lymphocytic leukemia. METHODS: We evaluated the expression of markers above on CLL by ELISA, qRT-PCR, flow cytometric analysis and nonparametric Kruskal-Wallis test. RESULTS: Quantitative RT-PCR revealed that the mRNA levels of IL-17A and IL-22 in PBMCs of CLL patients were upregulated compared with those from healthy subjects (mean ± SD: 1.96 ± 0.232 vs.0.72 ± 0.15, P < 0.001 and mean ± SD: 2.45 ± 0.534 vs.0.81 ± 0.26, P < 0.001, respectivily). In addition, findings showed that the IL-17A and IL-22 plasma level was significantly elevated than that from healthy control group (P < 0.001). The median IL-17A and IL-22 in CLL patients and healthy control group were 48.28 ± 17.2 pg mL-1 ; 20.01 ± 11.16 pg mL-1 and 58.68 ± 23.4 pg mL-1 ;16.47 ± 10.31 P < 0.001, respectively. The levels of IL-17A and IL-22 was not significantly associated with the different stages of disease (Rai stages; Kruskal-Wallis test P > 0.05).No significant relationship was found between expression of CD38 and higher median serum levels of IL-17A in patients, but patients with negative expression of ZAP-70 showed a significant association with higher median serum levels of IL-17A compared with healthy subjects. (57.84 pg mL-1 vs. 31.67 pg mL-1 ; P = 0.016). CONCLUSION:IL-22 is elevated and associated with CD38 and Zap-70 expression in patients with CLL. No significant correlation was found between expression of CD38 and increased levels of IL-17A, negative expression of ZAP-70 showed a significant association with increased levels of IL-17A.